Dynavax Technologies Corporation (DVAX) Coverage Initiated at Cantor Fitzgerald

Equities research analysts at Cantor Fitzgerald started coverage on shares of Dynavax Technologies Corporation (NASDAQ:DVAX) in a research report issued to clients and investors on Friday, September 15th, Marketbeat.com reports. The brokerage set an “overweight” rating and a $24.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 17.07% from the stock’s previous close.

DVAX has been the subject of several other research reports. Royal Bank Of Canada set a $7.00 price target on shares of Dynavax Technologies Corporation and gave the stock a “hold” rating in a research note on Wednesday, July 26th. Zacks Investment Research downgraded shares of Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. ValuEngine downgraded shares of Dynavax Technologies Corporation from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. William Blair restated an “outperform” rating on shares of Dynavax Technologies Corporation in a research note on Thursday, July 27th. Finally, Cowen and Company restated an “outperform” rating and issued a $30.00 price target on shares of Dynavax Technologies Corporation in a research note on Thursday, August 10th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Dynavax Technologies Corporation has an average rating of “Buy” and an average price target of $24.67.

Shares of Dynavax Technologies Corporation (NASDAQ DVAX) opened at 20.50 on Friday. Dynavax Technologies Corporation has a 12-month low of $3.20 and a 12-month high of $21.85. The firm’s 50-day moving average price is $17.84 and its 200-day moving average price is $9.78. The stock’s market cap is $1.12 billion.

Dynavax Technologies Corporation (NASDAQ:DVAX) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.09. The firm had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.15 million. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. During the same quarter last year, the firm earned ($0.75) EPS. On average, analysts forecast that Dynavax Technologies Corporation will post ($1.60) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Dynavax Technologies Corporation (DVAX) Coverage Initiated at Cantor Fitzgerald” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://ledgergazette.com/2017/09/24/dynavax-technologies-corporation-dvax-now-covered-by-cantor-fitzgerald.html.

Institutional investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC lifted its position in shares of Dynavax Technologies Corporation by 54.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 3,700 shares during the last quarter. Patriot Financial Group Insurance Agency LLC lifted its position in shares of Dynavax Technologies Corporation by 16.5% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 1,700 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in shares of Dynavax Technologies Corporation during the 1st quarter worth $121,000. Bank of America Corp DE lifted its position in shares of Dynavax Technologies Corporation by 2.3% during the 1st quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 456 shares during the last quarter. Finally, Legal & General Group Plc lifted its position in shares of Dynavax Technologies Corporation by 18.5% during the 2nd quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 1,950 shares during the last quarter. 60.20% of the stock is owned by institutional investors and hedge funds.

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Analyst Recommendations for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply